GPCR Stock: Price, Earnings History and SEC Filings
Structure Therapeutics Inc. (GPCR) last traded at $21.87, down 0.32% on the latest session and down 30.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.49 against an analyst estimate of $-0.39, a miss of 25.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
GPCR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.49 | $-0.39 | -25.64% |
| Mar 2026 | May 7, 2026 | $-0.35 | $-0.39 | +10.26% |
| Dec 2025 | Feb 26, 2026 | $-0.49 | $-0.35 | -40.00% |
| Sep 2025 | Nov 6, 2025 | $-0.37 | $-0.36 | -2.78% |
GPCR beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How GPCR reacts to earnings
Across its last 8 earnings releases, GPCR moved 2.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +0.99% |
| 2026-05-07 | After close | -0.13% |
| 2026-02-26 | After close | -2.73% |
| 2025-11-06 | After close | -1.88% |
| 2025-08-06 | After close | -0.67% |
| 2025-05-08 | After close | -4.66% |
| 2025-02-27 | After close | +4.08% |
| 2024-11-13 | After close | +3.63% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
GPCR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$141M | -$226M | – | $-0.80 |
| 2024 | – | -$123M | -$118M | – | $-0.78 |
| 2023 | – | -$90M | -$82M | – | $-0.81 |
| 2022 | – | -$51M | -$46M | – | $-5.51 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for GPCR
- 8-K · Sep 8, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 18, 2026Shareholder vote
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Material agreement, Results of operations, Other events
- 424B5 · May 7, 2026
- DEF 14A · Apr 23, 2026
- 8-K · Apr 15, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Mar 16, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
Insider filing activity
GPCR insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
GPCR news
- Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsOct 27, 2026 · finance.yahoo.com
- How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?Oct 21, 2026 · finance.yahoo.com
- Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026Oct 19, 2026 · finance.yahoo.com
- How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?Oct 19, 2026 · finance.yahoo.com
About Structure Therapeutics Inc.
Structure Therapeutics Inc. (GPCR) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Cayman Islands. Its fiscal year ends in December.